Results 41 to 50 of about 54,679 (264)

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

New England Journal of Medicine, 2018
BACKGROUND Nivolumab plus ipilimumab showed promising efficacy for the treatment of non–small‐cell lung cancer (NSCLC) in a phase 1 trial, and tumor mutational burden has emerged as a potential biomarker of benefit.
M. Hellmann, T. Ciuleanu, A. Płużański, J. Lee, G. Otterson, C. Audigier-Valette, E. Minenza, H. Linardou, S. Burgers, P. Salman, H. Borghaei, S. Ramalingam, J. Brahmer, M. Reck, K. O'Byrne, W. Geese, G. Green, Han-Cheng Chang, J. Szustakowski, P. Bhagavatheeswaran, D. Healey, Yali Fu, F. Nathan, L. Paz-Ares   +23 more
semanticscholar   +1 more source

Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial

Nature Medicine, 2022
Previous studies have suggested that the gut microbiome influences the response to checkpoint inhibitors (CPIs) in patients with cancer. CBM588 is a bifidogenic live bacterial product that we postulated could augment CPI response through modulation of ...
N. Dizman, L. Meza, P. Bergerot, Marice Alcantara, T. Dorff, Y. Lyou, P. Frankel, Yujie Cui, Valerie Mira, M. Llamas, J. Hsu, Z. Zengin, N. Salgia, S. Salgia, J. Malhotra, N. Chawla, A. Chehrazi-Raffle, R. Muddasani, J. Gillece, L. Reining, Jeff Trent, Motomichi Takahashi, K. Oka, S. Higashi, M. Kortylewski, S. Highlander, S. Pal   +26 more
semanticscholar   +1 more source

Acute visual loss after ipilimumab treatment for metastatic melanoma

Journal for ImmunoTherapy of Cancer, 2016
Background Ipilimumab, a humanized CLTA-4 antibody is a standard therapy in the treatment of advanced melanoma. While ipilimumab provides an overall survival benefit to patients, it can be associated with immune related adverse events (IrAEs).Case ...
Melissa A. Wilson, Kelly Guld, Steven Galetta, Ryan D. Walsh, Julia Kharlip, Madhura Tamhankar, Suzanne McGettigan, Lynn M. Schuchter, Leslie A. Fecher   +8 more
doaj   +1 more source

Significant Response to Nivolumab Plus Ipilimumab in Metastatic Mucinous Tubular and Spindle Cell Carcinoma: A Case Report. [PDF]

IJU Case Rep
ABSTRACT Introduction Mucinous tubular and spindle cell carcinoma (MTSCC) is a rare renal cell carcinoma subtype that is typically indolent but may exhibit aggressive behavior. No standard systemic therapy has been established for metastatic MTSCC. Case Presentation A 71‐year‐old woman underwent retroperitoneoscopic radical left nephrectomy for MTSCC ...
Shimasaki S, Yamamoto S, Iguchi M, Yamashita E, Atagi K, Shiba Y, Fukata S, Satake H, Karashima T, Inoue K.   +9 more
europepmc   +2 more sources

Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227

Journal of Clinical Oncology, 2022
PURPOSE We present 5-year results from CheckMate 227 Part 1, in which nivolumab plus ipilimumab improved overall survival (OS) versus chemotherapy in patients with metastatic non–small-cell lung cancer, regardless of tumor programmed death ligand 1 (PD ...
J. Brahmer, Jong-Seok Lee, T. Ciuleanu, R. Bernabé Caro, M. Nishio, L. Urban, C. Audigier-Valette, L. Lupinacci, R. Sangha, A. Płużański, J. Burgers, M. Mahave, Samreen Ahmed, A. Schoenfeld, L. Paz-Ares, M. Reck, H. Borghaei, K. O'Byrne, Ravi G. Gupta, J. Bushong, Li Li, S. Blum, Laura J. Eccles, S. Ramalingam   +23 more
semanticscholar   +1 more source

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

, 2022
Hepatology, EarlyView.
Robert J. Fontana, Iris Liou, Adrian Reuben, Ayako Suzuki, M. Isabel Fiel, William Lee, Victor Navarro   +6 more
wiley   +1 more source

Ipilimumab-Induced Enteritis without Colitis: A New Challenge

Case Reports in Oncology, 2016
Introduction: Ipilimumab is an immune checkpoint inhibitor targeting cytotoxic T-lymphocyte associated antigen 4 (CTLA4), approved to treat metastatic melanoma.
Marcus Messmer, Sunita Upreti, Yaman Tarabishy, Nikhilesh Mazumder, Reezwana Chowdhury, Mark Yarchoan, Matthias Holdhoff   +6 more
doaj   +1 more source

Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial—ECOG-ACRIN EA6134

Journal of Clinical Oncology, 2022
PURPOSE Combination programmed cell death protein 1/cytotoxic T-cell lymphocyte-4–blockade and dual BRAF/MEK inhibition have each shown significant clinical benefit in patients with BRAFV600-mutant metastatic melanoma, leading to broad regulatory ...
M. Atkins, Sandra J. Lee, B. Chmielowski, A. Tarhini, G. Cohen, T. Truong, H. Moon, D. Davar, M. O'Rourke, J. Stephenson, B. Curti, W. Urba, J. Brell, P. Funchain, K. Kendra, A. Ikeguchi, A. Jaslowski, C. Bane, Mark Taylor, Madhuri Bajaj, R. Conry, R. Ellis, T. Logan, N. Laudi, J. Sosman, David G. Crockett, A. Pecora, I. Okazaki, S. Reganti, S. Chandra, S. Guild, Helen X. Chen, H. Streicher, J. Wolchok, A. Ribas, J. Kirkwood   +35 more
semanticscholar   +1 more source

Ipilimumab: its potential in non-small cell lung cancer

Therapeutic Advances in Medical Oncology, 2012
Ipilimumab is a fully human monoclonal antibody that enhances antitumor immunity by way of cytotoxic T-lymphocyte antigen 4 blockade. It has already been approved by the US Food and Drug Administration for the treatment of metastatic melanoma and is ...
Pascale Tomasini, Nataliya Khobta, Laurent Greillier, Fabrice Barlesi   +3 more
doaj   +1 more source

Cost-effectiveness of nivolumab plus ipilimumab as first-line treatment for American patients with unresectable malignant pleural mesothelioma

Frontiers in Public Health, 2022
BackgroundThe treatment paradigm of unresectable malignant pleural mesothelioma (MPM) has changed in recent years. Checkmate 743 demonstrate that nivolumab plus ipilimumab showed good clinical benefits compared with chemotherapy in the treatment of MPM ...
Zhuo-miao Ye, Zi-Qing Tang, Zhe Xu, Qin Zhou, Huan Li   +4 more
doaj   +1 more source